Search results for "tips"

showing 10 items of 280 documents

Impact of Tips Preliver Transplantation for the Outcome Posttransplantation

2008

The effects of transjugular intrahepatic portocaval shunt (TIPS) on the survival of grafts and patients after liver transplantation (LTx) have only been documented in small series and with only a comparative description with non-TIPS recipients. We evaluated 61 TIPS patients who had a subsequent LTx and compared these with 591 patients transplanted with cirrhosis without TIPS. Pretransplant characteristics were similar between groups. Graft survival at 1, 3 and 5 years post-LTx was 85.2%, 77% and 72.1% (TIPS) and 75.3%, 69.8% and 66.1% (controls). Patient survival at the same points was 91.7%, 85% and 81.7%, respectively (TIPS) and 85.4%, 80.3% and 76.2% (controls). Cox regression showed th…

AdultMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationlaw.inventionPostoperative ComplicationslawmedicineTransjugular IntrahepaticHumansImmunology and AllergyPharmacology (medical)Prospective StudiesPortasystemic ShuntSurvival analysisTransplantationbusiness.industryProportional hazards modelLiver transplantation portal hypertension TIPSStentMiddle Agedmedicine.diseaseAdult; Female; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Survival Analysis; Liver Transplantation; Portasystemic Shunt Transjugular Intrahepatic; Treatment OutcomeSurvival AnalysisIntensive care unitLiver TransplantationSurgeryTransplantationTreatment OutcomePortal hypertensionFemalePortasystemic Shunt Transjugular IntrahepaticbusinessAmerican Journal of Transplantation
researchProduct

The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study…

2010

Abstract Background Atypical antipsychotics provide better control of the negative and affective symptoms of schizophrenia when compared with conventional neuroleptics; nevertheless, their heightened ability to improve cognitive dysfunction remains a matter of debate. This study aimed to examine the changes in cognition associated with long-term antipsychotic treatment and to evaluate the effect of the type of antipsychotic (conventional versus novel antipsychotic drugs) on cognitive performance over time. Methods In this naturalistic study, we used a comprehensive neuropsychological battery of tests to assess a sample of schizophrenia patients taking either conventional (n = 13) or novel a…

AdultMalemedicine.medical_specialtyCognition disorderslcsh:RC435-571Teràpia cognitivamedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticPilot ProjectsComorbidityCognitive therapyNeuropsychological TestsTrastorns de la cogniciólcsh:PsychiatryResearch articlemedicineHumansVerbal fluency testLongitudinal StudiesAntipsychotic drugsEffects of sleep deprivation on cognitive performancePsychiatryAntipsychoticRetrospective StudiesPsychiatric Status Rating ScalesCognitionExecutive functionsmedicine.diseasePsychiatry and Mental healthTreatment OutcomeSchizophreniaSchizophreniaFemaleSchizophrenic PsychologyAntipsicòticsEsquizofrèniaVerbal memoryCognition DisordersPsychologyAntipsychotic AgentsClinical psychologyBMC Psychiatry
researchProduct

Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. …

2009

Combining measurements of the monoamine metabolites in the cerebrospinal fluid (CSF) and neuroimaging can increase efficiency of drug discovery for treatment of brain disorders. To address this question, we examined five drug-naive patients suffering from schizophrenic disorder. Patients were assessed clinically, using the Positive and Negative Syndrome Scale (PANSS): at baseline and then at weekly intervals. Plasma and CSF levels of quetiapine and norquetiapine as well CSF 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindole-acetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were obtained at baseline and again after at least a 4 week medication trai…

AdultMalemedicine.medical_specialtyDibenzothiazepinesFluorine RadioisotopesPyrrolidinesmedicine.drug_classCaudate nucleusAtypical antipsychoticPilot ProjectsTritiumMethoxyhydroxyphenylglycolchemistry.chemical_compoundQuetiapine FumarateYoung AdultInternal medicinemedicineHumansBiogenic MonoaminesBiological PsychiatryTemporal cortexFirst episodeBrain Mappingbusiness.industryReceptors Dopamine D2Homovanillic acidHomovanillic AcidMiddle AgedMagnetic Resonance ImagingPsychiatry and Mental healthMonoamine neurotransmitterEndocrinologyFallypridechemistryPositron-Emission TomographyBenzamidesSchizophreniaQuetiapine34-Dihydroxyphenylacetic Acidbusinessmedicine.drugAntipsychotic AgentsProtein BindingJournal of psychiatric research
researchProduct

Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.

2005

Amisulpride is a clinically effective antipsychotic drug in a broad dose range with low propensity for extrapyramidal symptoms (EPS). Daily doses and plasma levels of amisulpride were analyzed within a large-scale therapeutic drug monitoring (TDM) survey to find plasma level ranges for optimized treatment under naturalistic conditions. Data of 378 schizophrenic patients treated with amisulpride (100-1550 mg) were included (40% female). Amisulpride plasma levels were analyzed at steady state; assessment comprised improvement (CGI-I) and side-effects, particularly EPS. For detection of cut-off values regarding non-response or EPS, receiver operating characteristics (ROC) curves were applied a…

AdultMalemedicine.medical_specialtyDyskinesia Drug-InducedAdolescentmedicine.drug_classStatistics as TopicAtypical antipsychoticPharmacologyGastroenterologyExtrapyramidal symptomsInternal medicineGermanymedicineHumansAmisulprideBiological PsychiatryAgedRetrospective StudiesAged 80 and overNeurologic ExaminationPsychiatric Status Rating ScalesReceiver operating characteristicmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryDopamine antagonistMiddle Agedmedicine.diseasePsychiatry and Mental healthDose–response relationshipROC CurveSchizophreniaTherapeutic drug monitoringSchizophreniaFemalemedicine.symptomAmisulprideDrug MonitoringSulpiridebusinessmedicine.drugAntipsychotic AgentsJournal of psychiatric research
researchProduct

Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclo…

2008

To elucidate the Batypicality( of ziprasidone, its striatal and extrastriatal D2/D3-receptor binding was characterized in patients with schizophrenia under steady-state conditions. These data were compared with striatal receptor occupancy values after single-dose ziprasidone ingestion in healthy controls. ( 18 F)fallypride positron emission tomography (PET) recordings were obtained in 15 patients under steady-state ziprasidone treatment at varying time points after the last dose. Binding potentials were calculated for striatal and extrastriatal regions. D2/D3-receptor occupancies were expressed relative to binding potentials in 8 unmedicated patients. In a parallel ( 11 C)raclopride-PET stu…

AdultMalemedicine.medical_specialtyFluorine RadioisotopesPyrrolidinesTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyBinding CompetitiveBasal GangliaPiperazinesYoung AdultDopamine receptor D3Internal medicinemedicineHaloperidolHumansPharmacology (medical)ZiprasidoneCarbon RadioisotopesTemporal cortexRacloprideDose-Response Relationship DrugChemistryReceptors Dopamine D2Dopamine antagonistReceptors Dopamine D3Psychiatry and Mental healthThiazolesEndocrinologyFallyprideRaclopridePositron-Emission TomographyBenzamidesSchizophreniaDopamine AntagonistsFemaleRadiopharmaceuticalsmedicine.drugAntipsychotic AgentsJournal of clinical psychopharmacology
researchProduct

Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders : Valid predictors of symptomatic response and remiss…

2010

To examine quality of life and subjective well-being as predictors of symptomatic treatment outcome.Biweekly PANSS ratings were performed in 285 inpatients with schizophrenia spectrum disorders within a multicenter trial by the German Research Network on Schizophrenia. Quality of life and subjective well-being were assessed using the Medical Outcomes Study-Short Form 36-Item Health Survey (SF-36), the Subjective Well-being Under Neuroleptic Treatment Scale (SWN-K) and the Adjective Mood Scale (AMS). Response was defined as an initial 20% PANSS total score reduction and remission according to the consensus criteria. Correlation analysis, logistic regression and CART-analysis were performed.I…

AdultMalemedicine.medical_specialtyMedizinLogistic regressionMood scale03 medical and health sciencesYoung Adult0302 clinical medicineQuality of lifeMulticenter trialInternal medicinemedicineHumansSubjective well-beingBiological PsychiatryPsychiatric Status Rating ScalesMiddle Agedmedicine.diseasePrognosisAntidepressive Agents3. Good health030227 psychiatryHospitalizationPsychiatry and Mental healthTranquilizing AgentsPsychotic DisordersSchizophreniaCorrelation analysisQuality of LifeSchizophreniaDrug Therapy CombinationFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgerySchizophrenia spectrumClinical psychologyAntipsychotic Agents
researchProduct

Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.

1998

Clozapine is a drug with many side effects, some of them with potentially hazardous outcome (e.g. seizures, agranulocytosis), if not carefully monitored. It has been shown that the metabolism of clozapine may be affected by concomitant treatment with selective serotonin reuptake inhibitors (SSRIs), while there have been reports of improved efficacy on negative symptomatology of clozapine in combination with SSRIs. Therefore, this prospective open clinical trial was performed to investigate the safety and tolerability of the coadministration of clozapine and paroxetine under control of serum concentrations of clozapine and its metabolites and the effect of this combination treatment on psych…

AdultMalemedicine.medical_specialtyPharmacologyPharmacotherapyInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyClozapineBiological PsychiatryClozapinePharmacologymedicine.diseaseParoxetineClinical trialPsychiatry and Mental healthParoxetineNeurologyTolerabilitySchizophreniaConcomitantSchizophreniaDrug Therapy CombinationFemaleNeurology (clinical)PsychologySelective Serotonin Reuptake Inhibitorsmedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response

2008

The aim of the present study was to examine the relevance of depressive symptoms during an acute schizophrenic episode for the prediction of treatment response. Two hundred inpatients who fulfilled DSM-IV criteria for schizophrenia or schizophreniform disorders were assessed at hospital admission and after 6 weeks of inpatient treatment using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Rating Scale for Depression (HAM-D). Depressive symptoms showed positive correlations with both positive and negative symptoms at admission and after 6 weeks, and decreased during 6 weeks of treatment. Pronounced depressive symptoms (HAM-D score> or =16) were found in 28% of the sample a…

AdultMalemedicine.medical_specialtyPsychosis610 Medicine & healthComorbidity10056 Clinic for Clinical and Social Psychiatry Zurich West (former)law.invention2738 Psychiatry and Mental Health03 medical and health sciencesPatient Admission0302 clinical medicineRandomized controlled triallawInternal medicinemental disordersmedicineHumansSchizophreniform disorderPsychiatryBiological PsychiatryDepression (differential diagnoses)ProbabilityPsychiatric Status Rating ScalesDepressive DisorderDepressive Disorder MajorPsychotropic DrugsPositive and Negative Syndrome ScaleHamilton Rating Scale for Depressionmedicine.diseaseComorbidity030227 psychiatryDiagnostic and Statistical Manual of Mental DisordersHospitalizationPsychiatry and Mental healthTreatment OutcomePsychotic DisordersSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychology2803 Biological Psychiatry030217 neurology & neurosurgeryAntipsychotic AgentsFollow-Up Studies
researchProduct

Gender-specific associations of depression with positive and negative symptoms in acute schizophrenia

2006

This clinical study analyzed gender-specific relationships of depression with other psychopathological and clinical variables in hospitalized patients with schizophrenia. During clinical routine treatment 119 inpatients with acute schizophrenia (DSM-IV) were investigated with the Calgary Depression Rating Scale for Schizophrenia (CDSS), the Clinical Global Impressions (CGI), and the Positive and Negative Syndrome Scale (PANSS). Depression scores of 77 male and 42 female patients (mean age 31.6+/-10.3 years) were related to background variables and to positive and negative symptom scores. Mean CDSS (5.8+/-5.6) and PANSS scores (total 76.9+/-22.1, positive symptoms 17.6+/-7.6, negative sympto…

AdultMalemedicine.medical_specialtyPsychosisAdolescentAcute schizophreniaRating scaleInternal medicinemental disordersmedicineHumansBiological PsychiatryDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesPharmacologySex CharacteristicsPositive and Negative Syndrome ScaleDepressionLength of StayMiddle Agedmedicine.diseaseAntidepressive AgentsHospitalizationSchizophreniaAcute DiseaseSchizophreniaRegression AnalysisFemaleSchizophrenic PsychologyPsychologyAntipsychotic AgentsPsychopathologyClinical psychologySex characteristicsProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Pseudoneglect in schizophrenia: A line bisection study with cueing

2007

Numerous authors have reported the existence of lateralised abnormalities towards the right side in patients with schizophrenia.In the present study, a manual line bisection task was used to assess the existence of a visuospatial bias in patients with schizophrenia as compared to healthy subjects and left unilateral neglect patients. In addition, we used a local cueing paradigm (consisting of a number placed on the right, on the left, or at both ends of the line).Healthy subjects showed a leftwards trend in the "no cue" condition (known as pseudoneglect) and neglect patients showed a right bias in all cue conditions. In contrast, patients with schizophrenia placed their manual estimation of…

AdultMalemedicine.medical_specialtyPsychosisCognitive Neurosciencemedia_common.quotation_subjectSchizophrenia (object-oriented programming)AudiologyNeglectPerceptual DisordersmedicineHumansIn patientmedia_commonHealthy subjectsSpace perceptionCognitionMiddle Agedmedicine.diseasePsychiatry and Mental healthUnilateral neglectSpace PerceptionSchizophreniaVisual PerceptionFemaleCuesVisual FieldsPsychologyAntipsychotic AgentsCognitive psychologyCognitive Neuropsychiatry
researchProduct